Articles

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study

Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Italy
Department of Haematology, University College London, UK
Day Hospital Talassemia, Ospedale Pediatrico Microcitemico “A. Cao”, A.O. “G. Brotzu”, Cagliari, Italy
Centro della Microcitemia, Ospedali Galliera, Genova, Italy
Thalassemia Center, Laikon General Hospital, Athens, Greece
UMGGR, Hôpital Henri Mondor; Assistance Publique-Hôpitaux de Paris (APHP); UPEC, Créteil, France
Department of Internal Medicine, American University of Beirut Medical Center, Lebanon
Department of Internal Medicine, APHP, Hôpital Européen Georges-Pompidou, Paris, France;INSERM UMR1163, CNRS ERL 8254, Institut Imagine, Université Paris Descartes-Sorbonne Paris Cité, France;Laboratory of Excellence GR-Ex, Paris, France
Laboratory of Onco-hematology, Hôpital Necker-Enfants Malades, Paris, France
Department of Haematology, University College London, UK
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Italy
Laboratory of Onco-hematology, Hôpital Necker-Enfants Malades, Paris, France
Laboratory of Onco-hematology, Hôpital Necker-Enfants Malades, Paris, France
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Boudry, Switzerland
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, San Francisco, CA, USA
Celgene Corporation, Boudry, Switzerland
Acceleron Pharma, Cambridge, MA, USA
INSERM UMR1163, CNRS ERL 8254, Institut Imagine, Université Paris Descartes-Sorbonne Paris Cité, France;Laboratory of Excellence GR-Ex, Paris, France;Department of Hematology, APHP, Hôpital Necker, Paris, France
Vol. 104 No. 3 (2019): March, 2019 https://doi.org/10.3324/haematol.2018.198887